The European Commission has signed a contract with US pharmaceutical giant Gilead, securing 30,000 doses of the COVID-19 drug remdesivir for EU member states and Britain. Remdesivir is the first drug that received EU approval to treat severe cases of COVID-19, the disease caused by the coronavirus. The €63-million ($74-million) contract will be paid for with an emergency instrument from the European Union’s shared budget, the EU’s executive body announced on Wednesday. Stella Kyriakides, EU Commissioner for health, called this move “another important step forward in our fight to overcome this disease”, and said the contract between the commission and...
